Rare Daily Staff
The National Leiomyosarcoma Foundation said it is launching the NLMSF International LMS Research Roundtable, an effort intended to accelerate the development of therapies for the rare cancer.
Leiomyosarcomas are rare malignant tumors that grow from immature smooth muscle cells, accounting for up to 20 percent of all soft tissue sarcomas. They appear most often in large blood vessels and the pelvic area, including the uterus, and, to a lesser extent, in the extremities like the thighs. In its metastatic state, leiomyosarcoma most commonly spreads to the bloodstream, lung, and liver.
Starting in 2019, the foundation will convene an annual roundtable consisting of researchers, clinicians, and pathologists from around the world to create a collaborative setting to advance treatment options in the hopes of making leiomyosarcomas a chronic, manageable disease. The foundation hopes the effort will lead to therapeutic options that lengthen survivorship of leiomyosarcoma patients.
The organization said sarcoma researchers believe that a deep dive into the still unanswered questions about the complexities of this particular sarcoma subtype is necessary to advance research endeavors for future development of targeted therapies and immunotherapies, and to amplify and improve treatment options for greater success.
September 24, 2018